The Trump administration’s latest round of most-favored-nation drug pricing deals, announced August 31, 2026, brought the number of participating manufacturers to 26. The agreements lower what state Medicaid programs pay for brand-name drugs from those companies, and they lower list prices for patients buying directly through the federal TrumpRx website. But read the fine print in the White House’s own announcement, and in the legal and policy analysis written since, and the reach looks narrower than the headline number suggests: private insurance formularies and Medicare’s drug benefit are not part of these deals, and the bills that come out of them look about the same as before.
What the Deals Actually Change
The White House’s own fact sheet is specific about where the new pricing reaches: it says the agreements “will provide every State Medicaid program in the country access to MFN drug prices” on products made by the nine newly added manufacturers, and it separately touts savings through TrumpRx, the direct-to-consumer purchasing site the administration launched in February 2026. It also cites a program that, since July 2026, has let seniors “without access to GLP-1 coverage” buy weight-loss and diabetes drugs for $50 a month in cash; the administration says more than 500,000 seniors used it in its first two months and saved a combined $216 million. Every dollar figure the White House attaches to this announcement traces back to one of those two channels — Medicaid or a cash purchase outside of insurance — not to an insurance claim. The fact sheet separately credits TrumpRx overall with more than $700 million in patient savings since its February 2026 launch, again a cash-purchase total, not a figure describing what any insurance plan now charges its members.
Free retirement updates: Enrollment and claim windows come and go, and missing one can cost you real money. The free Retirement Shield newsletter keeps you ahead of the deadlines that matter. Sign up free.
The Cash-Pay Discounts That Are Real and Specific
The clearest evidence that these deals do move a real price comes from the prior round. The December 19, 2025 fact sheet lists specific TrumpRx list-price cuts tied to that round’s nine manufacturers: the cholesterol drug Repatha from $573 to $239, the HIV medication Reyataz from $1,449 to $217, and the hepatitis C drug Epclusa from $24,920 to $2,425, all for patients paying cash through the federal site. Those cuts are documented and dated. What they are not is a change to what a private insurance plan charges a member in copay or coinsurance for the same drug, or what Medicare Part D pays a pharmacy for it — TrumpRx is a separate, cash-only purchasing channel that exists alongside, not inside, a person’s regular coverage.
Why Medicare Part D and Private Insurance Sit Outside These Deals
Medicare’s prescription drug prices already run through a different federal process entirely: the Medicare Drug Price Negotiation Program created by the 2022 Inflation Reduction Act, which negotiates prices for a separate, government-selected list of drugs on its own multi-year schedule. A legal alert from Duane Morris LLP, published two days after the August announcement, states plainly that the Medicare negotiation program and the MFN initiative “arise from different legal and policy mechanisms.” A manufacturer signing an MFN deal with the White House has not agreed to change what it charges Medicare or a private insurer’s pharmacy benefit manager; those prices are set through separate rebate and formulary negotiations the August agreements do not touch. Two proposed federal models, known as GLOBE and GUARD, have been floated as ways to eventually extend international reference pricing into Medicare Part B and Part D, but neither has been finalized or put into effect — so for now, a Medicare enrollee’s drug coverage runs on the same pricing rules it did before August 31.
Why Even Medicaid’s Own Savings May Run Smaller Than the Headline
There is also a reason to expect Medicaid’s realized savings to land below what the topline numbers imply. Speaking on a Medicare and Medicaid drug-pricing panel recapped by the trade publication AJMC, Vanderbilt health policy professor Stacie Dusetzina cautioned that Medicaid, which already receives mandatory manufacturer rebates under federal law, “might already be paying less than the MFN benchmark” for many drugs — meaning a new MFN price floor does not automatically produce new savings on top of a rebate Medicaid was already getting. That is a structural reason a national count of manufacturers and market share can be accurate while the savings that actually show up in a state Medicaid budget, or at an individual pharmacy counter, are smaller and slower to appear.
The Pass-Through Question Nobody Has Answered Yet
Even where a price genuinely falls, pharmacies do not automatically pass a lower manufacturer price on to a patient’s bill. The Duane Morris alert notes that pharmacy reimbursement “frequently depends upon contractual formulas, published pricing benchmarks, maximum allowable cost methodologies, dispensing fees … that may not move in tandem with changes to manufacturer pricing,” and that “important questions remain” about how savings will ultimately reach patients. That is the honest state of the record eight days after the announcement: a confirmed, named list of 26 manufacturers and a confirmed cash-pay and Medicaid channel where discounts are documented — alongside Medicare drug coverage and private insurance pricing that this particular round of deals never touched at all.
This article was produced with AI assistance and reviewed by a human editor. Figures are linked to their primary sources; where a claim could not be verified from the public record, we say so.
More Financial Reading
